The high PE ratio of AstraZeneca suggests that the market has high expectations of the company, which may lead to overvaluation. The low PB and PS ratios suggest that the company's stock is undervalued in terms of its book value and sales, indicating potential for price appreciation. However, the low ROE, EBITDA, and gross profit suggest potential inefficiency and weak operating performance, which could negatively impact the stock price. Despite this, the high revenue growth compared to its peers suggests potential future growth, which could positively impact the stock price.